Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

What Should You Avoid Before a PSA Test?

Latest Prostate Cancer News and Research

Genetic test outperforms PSA and MRI in spotting deadly prostate cancer early

A UK study found that using a polygenic risk score to identify men at highest genetic risk of prostate cancer significantly improved detection of clinically important disease. This approach caught aggressive cancers that standard PSA and MRI screening would have missed.

10 Apr 2025

Laser-based infrared molecular fingerprinting detects common cancers

Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies.

9 Apr 2025

Gut bacteria may reduce the effectiveness of common medications

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

3 Apr 2025

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.

2 Apr 2025

New drug target identified for treating acute myeloid leukemia

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly blood cancer with a five-year survival rate of just 30%, according to the National Cancer Institute.

2 Apr 2025

Football proven to prevent and treat lifestyle diseases

Danish researchers, in collaboration with the Danish Football Association, have released a White Paper that describes football as an effective recipe in the prevention and treatment of lifestyle-related diseases.

2 Apr 2025

Study links linoleic acid to triple-negative breast cancer growth

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat "triple negative" breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators.

1 Apr 2025

World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with technetium-99m to detect cancerous lesions in men with prostate cancer.

31 Mar 2025

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period.

29 Mar 2025

New research sheds light on prostate cancer resistance mechanisms

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime.

27 Mar 2025

Colorectal cancer burden climbs in countries with low milk intake

A global study finds that low milk intake is linked to increased colorectal cancer burden, especially in older adults. Prostate cancer rates showed negative trends, though the findings may reflect model limitations rather than protective effects.

26 Mar 2025

Scientists uncover role of m6A in prostate cancer progression

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny chemical modification in RNA, known as m6A, plays a critical role in the progression of prostate cancer, including driving some of its most dangerous forms of the disease.

24 Mar 2025

New technique doubles erectile function preservation in prostate surgery

A technique to improve the precision of prostate cancer surgery means that almost twice as many men preserve their erectile function compared to those undergoing standard surgery, according to results from a clinical trial led by researchers from UCL and UCLH.

24 Mar 2025

Micro-ultrasound proves as effective as MRI in prostate cancer diagnosis

Biopsies guided by high resolution ultrasound are as effective as those using MRI in diagnosing prostate cancer, an international clinical trial has shown.

24 Mar 2025

Avoiding prostate cancer screening increases risk of death

Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group.

20 Mar 2025

$1 million CPRIT grant focuses on AI to improve prostate cancer outcomes

Erzsébet Merényi, a statistics research professor at Rice University, and co-investigators at The University of Texas MD Anderson Cancer Center Pratip Bhattacharya, professor of cancer systems imaging, and Dr. Patrick Pilié, assistant professor of genitourinary medical oncology, were awarded $1 million by the Cancer Prevention and Research Institute of Texas (CPRIT) to develop artificial intelligence (AI) tools that can identify lethal forms of prostate cancer earlier and improve treatment selection.

18 Mar 2025

AI could play a key role in improving prostate cancer treatment outcomes

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

18 Mar 2025

Current PSA monitoring guidelines may lead to overtreatment after prostate surgery

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels.

13 Mar 2025

Why do some people need supplements and others don’t? New review explains

New research in The New England Journal of Medicine reviews current knowledge on micronutrient requirements, deficiencies, and interventions. It highlights the need for targeted supplementation and calls for advanced research to better diagnose and treat hidden deficiencies.

9 Mar 2025

EZH2 inhibition offers hope for fighting treatment-resistant cancers

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases.

8 Mar 2025